Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Highlights in AML and MDS from EHA 2022

Shai Shimony , MD, Dana-Farber Cancer Institute, Boston, MA, shares some key highlights in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) from the EHA 2022 meeting. Dr Shimony first comments on the excitement around the novel Molecular International Prognostic Scoring System (IPSS-M) in MDS, and further discusses clinical trial updates from the meeting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.